Comparative efficacy of liver resection vs. radiofrequency ablation for small hepatocellular carcinoma stratified by alpha-fetoprotein status: a retrospective cohort study using restricted mean survival time and number needed to treat analysis.
{"title":"Comparative efficacy of liver resection <i>vs</i>. radiofrequency ablation for small hepatocellular carcinoma stratified by alpha-fetoprotein status: a retrospective cohort study using restricted mean survival time and number needed to treat analysis.","authors":"Hong Chen, Junbin Zhou","doi":"10.21037/tcr-2026-0781","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The choice between liver resection (LR) and radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) ≤3 cm remains controversial. This study evaluated whether alpha-fetoprotein (AFP) status modulates the comparative efficacy of these modalities using absolute benefit metrics.</p><p><strong>Methods: </strong>Patients with T1N0M0 HCC (≤3 cm) treated with LR or RFA were identified from the Surveillance, Epidemiology, and End Results (SEER) program database. After 1:1 propensity score matching (PSM), cancer-specific survival (CSS) and overall survival (OS) were analyzed. Restricted mean survival time (RMST) and number needed to treat (NNT) were utilized to quantify the absolute clinical gain of LR over RFA.</p><p><strong>Results: </strong>Among 1,119 identified patients, 235 matched pairs were analyzed. LR demonstrated superior survival in the overall cohort (P<0.001). A significant interaction was observed between treatment modality and AFP status (P<sub>interaction</sub><0.01). In AFP-negative patients, LR provided a profound survival advantage [CSS: hazard ratio (HR) =0.362; 95% confidence interval (CI): 0.220-0.594; P<0.001], translating into a substantial RMST extension of 8.1 months and a low NNT of 4. Conversely, in the AFP-positive subgroup, this surgical advantage was notably attenuated (CSS: HR =0.800; 95% CI: 0.555-1.152; P=0.23), with the RMST extension dropping to 3.5 months and the NNT increasing to 12.</p><p><strong>Conclusions: </strong>The superiority of LR over RFA in small HCC is significantly modulated by AFP-defined tumor biology. AFP-negative patients derive profound absolute survival gains from surgery, whereas benefits in AFP-positive cases are marginal, supporting RFA as a viable alternative for biologically aggressive tumors.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"646"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559617/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2026-0781","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The choice between liver resection (LR) and radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) ≤3 cm remains controversial. This study evaluated whether alpha-fetoprotein (AFP) status modulates the comparative efficacy of these modalities using absolute benefit metrics.
Methods: Patients with T1N0M0 HCC (≤3 cm) treated with LR or RFA were identified from the Surveillance, Epidemiology, and End Results (SEER) program database. After 1:1 propensity score matching (PSM), cancer-specific survival (CSS) and overall survival (OS) were analyzed. Restricted mean survival time (RMST) and number needed to treat (NNT) were utilized to quantify the absolute clinical gain of LR over RFA.
Results: Among 1,119 identified patients, 235 matched pairs were analyzed. LR demonstrated superior survival in the overall cohort (P<0.001). A significant interaction was observed between treatment modality and AFP status (Pinteraction<0.01). In AFP-negative patients, LR provided a profound survival advantage [CSS: hazard ratio (HR) =0.362; 95% confidence interval (CI): 0.220-0.594; P<0.001], translating into a substantial RMST extension of 8.1 months and a low NNT of 4. Conversely, in the AFP-positive subgroup, this surgical advantage was notably attenuated (CSS: HR =0.800; 95% CI: 0.555-1.152; P=0.23), with the RMST extension dropping to 3.5 months and the NNT increasing to 12.
Conclusions: The superiority of LR over RFA in small HCC is significantly modulated by AFP-defined tumor biology. AFP-negative patients derive profound absolute survival gains from surgery, whereas benefits in AFP-positive cases are marginal, supporting RFA as a viable alternative for biologically aggressive tumors.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
